Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa-and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.
INTRODUCTION
High-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) is an established treatment for lymphoma, especially in relapse after conventional chemotherapy.
1-4 BEAM (carmustine, etoposide, cytarabine, melphalan) is the most commonly used regimen for high-dose therapy (HDT) before auto-SCT. However, it is accompanied by relevant toxicity, for example, mucositis and dose-dependent pulmonal toxicity of carmustine. For this reason, alternative conditioning regimens are being evaluated.
Thiotepa (TT) is an alkylating agent approved for conditioning/ high-dose preparation before allogeneic and autologous hematopoietic SCT. Because of its excellent capacity to cross the blood-brain barrier, it is regularly used as part of HDT followed by auto-SCT for primary central nervous system lymphoma (PCNSL). [5] [6] [7] Although TT-based myeloablation might compare well with other conventionally used high-dose regimens such as BEAM, clinical-level information about TT-based auto-SCT outside the PCNSL field is sparse. The purpose of the present retrospective study based on the European Society for Blood and Marrow Transplantation (EBMT) database was to provide information on the potential risks and benefits of TT-based high-dose regimens for auto-SCT in distinct subtypes of lymphoma outside the PCNSL setting.
patients to a central registry in which patients may be identified by the diagnosis of underlying disease and type of transplantation. Informed consent for transplantation and data collection was obtained locally according to regulations applicable at the time of transplantation. Since January 2003, all transplant centers have been required to obtain written informed consent before data registration with the EBMT following the Declaration of Helsinki (1975) .
Study design
This was a registry-based retrospective multicenter study including patients 18 years or above who underwent a first auto-SCT with the diagnosis of diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL), Hodgkin lymphoma (HL) or peripheral T-cell lymphoma (PTCL) between 2003 and 2011, had received either BEAM-or TT-based HDT and had peripheral blood as stem cell source. The main objectives were to compare the safety and efficacy of TT-based HDT with that of BEAM using risk-matched patient populations.
Data collection
The study was based on MED-A level information. However, for deeper comparison of the toxicity profiles of BEAM and TEAM (thiotepa, etoposide, cytarabine, melphalan) ( = BEAM using TT instead of carmustine), we additionally sent questionnaires to participating centers for all patients identified in the database as having received TEAM as well as for their respective BEAM matches. These included additional baseline information as well as treatment and toxicity details.
Statistical analysis
Patients with TT-based or TEAM HDT were matched with patients having received BEAM in a 1:2 ratio using the following matching factors: gender, age (±10 years), lymphoma subtype, time from diagnosis to transplant (±10 months), disease status at transplant, year of auto-SCT and performance status (including missing category).
The matched analysis of TT-based vs BEAM-only used basic information (MED-A level) registered in the EBMT database. For the matched analysis of TEAM vs BEAM, TEAM patients were identified in the EBMT database and matched 1:2 with BEAM patients using the matching factors mentioned above. Centers with TEAM or BEAM patients eligible after matching were contacted to provide additional data, including toxicity and updated follow-up information.
Primary end points for both comparisons were progression free survival (PFS) and overall survival (OS) calculated from auto-SCT in each of the four lymphoma subtypes. Secondary end points were non-relapse mortality (NRM) and incidence of relapse (RI) in each of the subsets and as pooled data of all four subsets. In the comparison BEAM vs TEAM, early toxicity (mucositis, nausea, vomiting during conditioning and early post-transplant phase; pneumonia and other infectious complications up to day +100; pneumonitis and other non-infectious complications up to day +100) was additionally evaluated as a secondary end point. Abbreviations: BEAM = carmustine, etoposide, ara-C, melphalan; CR1 = first CR; CR41 = CR in relapse; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; HL = Hodgkin's lymphoma; PR1 = first PR; PR41 = PR in relapse; PTCL = peripheral T-cell lymphoma; SCT = stem cell transplantation; TT = thiotepa.
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To study the association of patient and transplant variables with primary end points, univariate and multivariate analyses were performed. For comparison of variables between groups, t-tests or Mann-Whitney U-tests were used as indicated. Survival curves for OS and PFS were estimated by the Kaplan-Meier method. For comparison of OS and PFS between TT-based vs BEAM and TEAM vs BEAM, a log-rank test stratified on pair was used. Cumulative incidence curves taking into account the competing risk structure of the event were estimated for NRM and RI. A pair-stratified Gray's test was used to compare NRM and RI between TT-based vs BEAM and TEAM vs BEAM. Adjusted hazard ratios (HRs) were estimated using pair-stratified Cox and pair-stratified Fine and Gray regression model, respectively, for OS/PFS and NRM/IR. The variables of the toxicity secondary end point underwent descriptive statistics and were compared by nonparametric tests. All P-values o 0.05 were considered significant. All statistical analyses were performed using R 2.15.3 (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org).
RESULTS

Patient characteristics
Altogether, 14 544 patients meeting the eligibility criteria were identified: 589 patients were treated with a TT-based regimen and 13 955 patients were treated with BEAM. After 1:2 matching, the final sample comprised 535 patients in the TT group and 1031 in the BEAM group (54 TT patients could not be matched, and for 39 only one match was found). Consequently, patient cohorts were well balanced for the matching factors with a predominance of DLBCL and a relatively large proportion of patients having received auto-SCT in first remission. Patient characteristics are detailed in Table 1 . TT-based regimens largely consisted of combinations of TT with various alkylating agents commonly used for high-dose preparation for auto-SCT. Details of the applied regimens are listed in Table 2 .
Outcome NRM after TT-based regimens and BEAM was low with 2% (95% confidence interval (95% CI): 1-4%) and 4% (95% CI: 3-6%) at 12 months after transplant (P = 0.81). Similarly, there were no significant differences between the TT and BEAM groups for any outcome end point when considering the whole sample (PFS: HR = 1. Table 3 . PFS, OS and RI at 30 months after auto-SCT for TEAM (n = 110) vs BEAM (n = 199)
were 49% (95% CI: 38-63%) vs 62% (95% CI: 54-70%), 77% (95% CI: 67-88%) vs 77% (95% CI: 71-84%) and 50% (95% CI: 37-61%) vs 37% (95% CI: 29-45%) with no significant differences ( Figure 4 ). There were five non-relapse deaths, one in the TEAM group and four in the BEAM group. Additional toxicity and follow-up information was received for 122 matched patients (47 TEAM and 75 BEAM). Characteristics of these 122 patients were not different from the whole-matched TEAM-BEAM sample, except for a longer follow-up in the TEAM subset (Supplementary Table 1 ). The frequency of common infectious and non-infectious complications including secondary malignancies was not significantly different between TEAM and BEAM (Table 4) . Non-engraftment was reported only for a single patient (of the BEAM group) and could be successfully rescued by a back-up autograft.
DISCUSSION
Auto-SCT is currently a standard treatment in relapsed lymphoma, [1] [2] [3] [4] with BEAM being the preferred and most widely adapted HDT regimen for transplant. Apart from specific safety concerns consisting of the pulmonary toxicity of carmustine, 8 the Abbreviations: BEAM = carmustine, etoposide, ara-C, melphalan; CR1 = first CR; CR41 = CR in relapse; DLBCL = diffuse large B-cell lymphoma; FL = follicular lymphoma; HL = Hodgkin's lymphoma; PR1 = first PR; PR41 = PR in relapse; TEAM = thiotepa, etoposide, ara-C, melphalan; SCT = stem cell transplantation. TT-based HDT is established for auto-SCT in PCNSL, [5] [6] [7] as well as for systemic non-Hodgkin lymphoma involving the CNS. 9 Acceptable safety profiles and decent efficacy of TT-based HDT regimens provide a rationale for investigating these as alternatives to BEAM also in patients with lymphoma other than PCNSL. Furthermore, the capacity of TT to pass the blood-brain barrier may allow optimizing the therapy of patients with CNS involvement or increased CNS relapse risk.
With 535 patients, our registry-based retrospective analysis is, to our knowledge, the largest comparative study on TT-based preparation for auto-SCT in this context. Especially comparative studies of BEAM-and TT-based preparation are small and sparse with only retrospective single-center experience in the literature. Two comparative studies on BEAM against a TT-based regimen have been published so far: in non-Hodgkin lymphoma (largely DLBCL), Zaucha et al.
10 compared 48 BEAM-treated patients with 59 patients having undergone an HDT regimen comprising busulfan, melphalan and TT. In HL, Ganguly et al.
11 compared 14 patients treated with BEAM or BEAC (carmustine, etoposide, cytarabine, cyclophosphamide) with 9 patients prepared with busulfan, melphalan and TT for auto-SCT. In both studies, toxicity profiles were, in part, less favorable for the busulfan, melphalan and TT group. Zaucha et al. 10 reported high rates of infectious and non-infectious grade III-IV toxicities for busulfan, melphalan and TT, mainly mucositis, gastrointestinal, pulmonary and hepatic, which was also seen in another, non-comparative study by Lee et al. 12 However, in both studies, the comparison groups were, in addition to their relatively small sample size, very unevenly distributed. For these reasons, only very limited conclusions can be drawn from these analyses.
In contrast, in the present study, two very homogeneous and well comparable groups of reasonable size were obtained by extensive matching. In keeping with published experience, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] the main combination partners of TT were carmustine, melphalan, busulfan and cyclophosphamide. No significant differences for any safety or efficacy end point could be demonstrated between BEAM-and TT-based regimens for the whole population as well as for relatively large groups of the DLBCL, HL and FL subentities, except a significantly higher relapse risk with TT in the DLBCL CR/PR1 subset (which is not a standard indication for auto-SCT). The latter finding might be because of the limitations of this first set of analyses, which consist in the heterogeneity of TT-based regimens and the lack of toxicity information beyond plain NRM. This led us to a take a closer look at the more homogeneous group of TEAM-treated patients including retrieval of additional toxicity data.
Nonetheless, also in the direct comparison of TEAM vs BEAM significant differences concerning outcome and toxicity did not emerge. A favorable toxicity profile for TEAM regarding pulmonary toxicity could have been assumed but was not confirmed in the present study. However, this has to be handled with caution because of the limited patient numbers in the BEAM-TEAM comparison, and because of the retrospective design of the study without standardized grading of toxicities.
Besides TT-based regimens, other alternatives to BEAM are currently being evaluated. For example, bendamustine was combined with etoposide, cytarabine, melphalan (BeEAM). In a phase I/II trial with 28 non-Hodgkin lymphoma and 15 HL patients, only moderate toxicity despite high response rates was seen with BeEAM (3-year PFS 72%). 21, 22 Unlike TT and carmustine, 23 however, there is little evidence that bendamustine can efficiently pass the intact blood-brain barrier in humans. Only limited reports without pharmacokinetic evaluation are available on efficacy of bendamustine in PCNSL. 24, 25 Therefore, this regimen may be less appropriate for patients with lymphoma at increased risk for CNS relapse such as testicular involvement, bulky disease, extranodal involvement and high serum lactate dehydrogenase levels. 26 In addition, BeEAM represents only a small increase of the bendamustine dose (o 2-fold) compared with the standard dose and this may not be sufficient to overcome resistance. Other efficient alternatives to BEAM are busulfan and cyclophosphamide with or without etoposide. [27] [28] [29] [30] In a recent large registry study with 4917 patients with lymphoma, outcomes of various commonly used high-dose regimens (BEAM, cyclophosphamide/ carmustine/etoposide, busulfan/cyclophosphamide, TBI-based), several significant but often only subtle outcome differences between different HDT platforms were found in individual non-Hodgkin lymphoma subsets. 31 Similarly, slight differences may exist between the comparators of the present study, which can be only detected on the basis of much larger samples or by prospective studies.
In summary, with the limitations of a retrospective registry analysis, these results indicate that efficacy and tolerability of TT-based regimens might be similar to that of conventional BEAM if used as high-dose preparation for auto-SCT in DLBCL, HL and FL. Thus, in these lymphoma subtypes TT-based HDT might be a valuable alternative to BEAM in situations where BEAM is unavailable or contraindicated. Further evaluation by prospective clinical trials is warranted and may help to identify subgroups that might benefit from a TT-based regimen such as TEAM. Abbreviations: BEAM = carmustine, etoposide, ara-C, melphalan; TEAM = thiotepa, etoposide, ara-C, melphalan.
